Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects With Chronic Plaque Psoriasis

Next Previous
Trial Profile

A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects With Chronic Plaque Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms DERMIS-2
  • Sponsors Arcutis Biotherapeutics

Most Recent Events

  • 20 Oct 2023 According to an Arcutis Biotherapeutics media release, pooled data analysis from DERMIS-1 and DERMIS-2 trials were presented at the 43rd Annual Fall Clinical Dermatology Conference held October 19-22, 2023, in Las Vegas, Nevada.
  • 20 Oct 2023 Results were presented in a Arcutis Biotherapeutics Media Release.
  • 09 May 2023 According to an Arcutis Biotherapeutics media release, the company anticipates potential FDA approval for sNDA for an expanded indication for the treatment of plaque psoriasis in children down to 2 years of age in the fourth quarter of 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top